Review



mfg e8 levels  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Boster Bio mfg e8 levels
    Mfg E8 Levels, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mfg e8 levels/product/Boster Bio
    Average 93 stars, based on 6 article reviews
    mfg e8 levels - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    91
    R&D Systems mfg e8 protein levels
    Mfg E8 Protein Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mfg e8 protein levels/product/R&D Systems
    Average 91 stars, based on 1 article reviews
    mfg e8 protein levels - by Bioz Stars, 2026-02
    91/100 stars
      Buy from Supplier

    93
    Boster Bio mfg e8 levels
    Mfg E8 Levels, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mfg e8 levels/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    mfg e8 levels - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    Boster Bio 217 elisa 218 mfg e8 levels
    217 Elisa 218 Mfg E8 Levels, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/217 elisa 218 mfg e8 levels/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    217 elisa 218 mfg e8 levels - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    R&D Systems serum mfg e8 levels
    Serum <t>MFG-E8</t> levels in patients with liver diseases. Serum milk fat globule-EGF factor 8 (MFG-E8) levels are shown for healthy volunteers (HVs) and hepatocellular carcinoma (HCC) patients ( A ), for HCC patients stratified by tumor size ( B ) by etiology of liver diseases ( C ), for hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected, post-sustained virologic response (SVR) and non-alcoholic fatty liver disease (NAFLD) patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCCs ( D ), and in patients with benign liver tumors (Benign), intrahepatic cholangiocarcinoma (ICC), or metastatic liver tumors derived from primary colon cancer (Meta) ( D ) and for HCC patients before and after surgery (solid line, n = 12) or radiofrequency ablation (dashed line, n = 7) ( E ). Box plots represent the interquartile range and whiskers show minimum and maximum values. The line in each box shows the median. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, † p < 0.0001 compared with HV by Kruskal-Wallis test with Dunn’s multiple comparison test. Paired Student’s t test was used for the analysis presented in ( E ).
    Serum Mfg E8 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/serum mfg e8 levels/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    serum mfg e8 levels - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    Serum MFG-E8 levels in patients with liver diseases. Serum milk fat globule-EGF factor 8 (MFG-E8) levels are shown for healthy volunteers (HVs) and hepatocellular carcinoma (HCC) patients ( A ), for HCC patients stratified by tumor size ( B ) by etiology of liver diseases ( C ), for hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected, post-sustained virologic response (SVR) and non-alcoholic fatty liver disease (NAFLD) patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCCs ( D ), and in patients with benign liver tumors (Benign), intrahepatic cholangiocarcinoma (ICC), or metastatic liver tumors derived from primary colon cancer (Meta) ( D ) and for HCC patients before and after surgery (solid line, n = 12) or radiofrequency ablation (dashed line, n = 7) ( E ). Box plots represent the interquartile range and whiskers show minimum and maximum values. The line in each box shows the median. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, † p < 0.0001 compared with HV by Kruskal-Wallis test with Dunn’s multiple comparison test. Paired Student’s t test was used for the analysis presented in ( E ).

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: Serum MFG-E8 levels in patients with liver diseases. Serum milk fat globule-EGF factor 8 (MFG-E8) levels are shown for healthy volunteers (HVs) and hepatocellular carcinoma (HCC) patients ( A ), for HCC patients stratified by tumor size ( B ) by etiology of liver diseases ( C ), for hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected, post-sustained virologic response (SVR) and non-alcoholic fatty liver disease (NAFLD) patients with chronic hepatitis (CH), liver cirrhosis (LC), and HCCs ( D ), and in patients with benign liver tumors (Benign), intrahepatic cholangiocarcinoma (ICC), or metastatic liver tumors derived from primary colon cancer (Meta) ( D ) and for HCC patients before and after surgery (solid line, n = 12) or radiofrequency ablation (dashed line, n = 7) ( E ). Box plots represent the interquartile range and whiskers show minimum and maximum values. The line in each box shows the median. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, † p < 0.0001 compared with HV by Kruskal-Wallis test with Dunn’s multiple comparison test. Paired Student’s t test was used for the analysis presented in ( E ).

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques: Virus, Infection, Derivative Assay, Comparison

    ROC analyses of serum MFG-E8, AFP, and DCP levels and our prediction model for diagnosis of HCC patients. ( A ) Receiver operating characteristic (ROC) curves for distinguishing hepatocellular carcinoma (HCC) patients (n = 185) from chronic hepatitis (CH)/ liver cirrhosis (LC) patients (n = 108). The optimal cutoff value for milk fat globule-EGF factor 8 (MFG-E8) was determined as those yielding the minimal value for (1 − sensitivity) 2 + (1 − specificity) 2 . ( B ) Venn diagram presenting the distribution of HCC patients according to MFG-E8, α-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP). ( C,D ) Performance assessment of our prediction model and other HCC tumor biomarkers for HCC for distinguishing HCC patients (n = 185) from CH/LC patients (n = 108) ( C ), and patients with HCCs smaller than 3 cm (n = 77) from CH/LC patients (n = 108) ( D ). AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: ROC analyses of serum MFG-E8, AFP, and DCP levels and our prediction model for diagnosis of HCC patients. ( A ) Receiver operating characteristic (ROC) curves for distinguishing hepatocellular carcinoma (HCC) patients (n = 185) from chronic hepatitis (CH)/ liver cirrhosis (LC) patients (n = 108). The optimal cutoff value for milk fat globule-EGF factor 8 (MFG-E8) was determined as those yielding the minimal value for (1 − sensitivity) 2 + (1 − specificity) 2 . ( B ) Venn diagram presenting the distribution of HCC patients according to MFG-E8, α-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP). ( C,D ) Performance assessment of our prediction model and other HCC tumor biomarkers for HCC for distinguishing HCC patients (n = 185) from CH/LC patients (n = 108) ( C ), and patients with HCCs smaller than 3 cm (n = 77) from CH/LC patients (n = 108) ( D ). AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques:

    The relationship between serum preoperative MFG-E8 levels and HCC recurrence or survival following hepatectomy. ( A ) Kaplan–Meier analysis of overall survival (OS) for patients stratified by early recurrence (ER) within 1 year of resection (n = 54) and no recurrence within 1 year of resection (n = 131). ( B ) Serum milk fat globule-EGF factor 8 (MFG-E8) levels for preoperative hepatocellular carcinoma (HCC) patients grouped by early recurrence (ER; n = 54), late recurrence (LR; n = 52), and no recurrence (NR; n = 79). (C,D) Kaplan–Meier analysis of disease free survival (DFS) ( C ) and overall survival (OS) ( D ) for HCC patients stratified by serum MFG-E8 levels (cut-off: 3.42 ng/mL). Box plots show the interquartile range and whiskers show the minimum and maximum values. The line in each box shows the median. *p < 0.05.

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: The relationship between serum preoperative MFG-E8 levels and HCC recurrence or survival following hepatectomy. ( A ) Kaplan–Meier analysis of overall survival (OS) for patients stratified by early recurrence (ER) within 1 year of resection (n = 54) and no recurrence within 1 year of resection (n = 131). ( B ) Serum milk fat globule-EGF factor 8 (MFG-E8) levels for preoperative hepatocellular carcinoma (HCC) patients grouped by early recurrence (ER; n = 54), late recurrence (LR; n = 52), and no recurrence (NR; n = 79). (C,D) Kaplan–Meier analysis of disease free survival (DFS) ( C ) and overall survival (OS) ( D ) for HCC patients stratified by serum MFG-E8 levels (cut-off: 3.42 ng/mL). Box plots show the interquartile range and whiskers show the minimum and maximum values. The line in each box shows the median. *p < 0.05.

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques:

    Correlation between serum  MFG-E8  level and clinicopathological features in 185 HCC patients.

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: Correlation between serum MFG-E8 level and clinicopathological features in 185 HCC patients.

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques:

    Factors associated with early recurrence after hepatectomy for HCC (n = 185).

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: Factors associated with early recurrence after hepatectomy for HCC (n = 185).

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques:

    Factors associated with overall survival after hepatectomy for HCC (n = 185).

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: Factors associated with overall survival after hepatectomy for HCC (n = 185).

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques:

    Serum MFG-E8 levels and EVs in HVs and HCC patients. ( A ) Extracellular vesicles (EVs) isolated using the Tim4 affinity method were analyzed by nanoparticle tracking analysis (NTA) using NanoSight LM10. ( B ) Expression of the EV markers CD63, CD9, CD81 and flotillin 1 by western blotting. Full-length blots are presented in Supplementary Fig. . ( C ) Comparision of serum milk fat globule-EGF factor 8 (MFG-E8) levels before and after EV isolation by the Tim4 affinity method. ( D ) Correlation between serum MFG-E8 levels and the concentration of serum EVs isolated using the Tim4 affinity method. Sera were drawn from healthy volunteers (HVs) (n = 20) and hepatocellular carcinoma (HCC) patients (n = 20). ( E ) Comparative analysis of serum EVs from HVs and HCC patients by NTA. ( F ) EVs isolated using the ultracentrifugation method were analyzed by NTA using NanoSight LM10. ( G ) Comparative analysis of serum EVs isolated by the ultracentrifugation method from HCC patients (n = 15) and HVs (n = 15). *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal-Wallis test with Dunn’s multiple comparison test.

    Journal: Scientific Reports

    Article Title: Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

    doi: 10.1038/s41598-019-52356-6

    Figure Lengend Snippet: Serum MFG-E8 levels and EVs in HVs and HCC patients. ( A ) Extracellular vesicles (EVs) isolated using the Tim4 affinity method were analyzed by nanoparticle tracking analysis (NTA) using NanoSight LM10. ( B ) Expression of the EV markers CD63, CD9, CD81 and flotillin 1 by western blotting. Full-length blots are presented in Supplementary Fig. . ( C ) Comparision of serum milk fat globule-EGF factor 8 (MFG-E8) levels before and after EV isolation by the Tim4 affinity method. ( D ) Correlation between serum MFG-E8 levels and the concentration of serum EVs isolated using the Tim4 affinity method. Sera were drawn from healthy volunteers (HVs) (n = 20) and hepatocellular carcinoma (HCC) patients (n = 20). ( E ) Comparative analysis of serum EVs from HVs and HCC patients by NTA. ( F ) EVs isolated using the ultracentrifugation method were analyzed by NTA using NanoSight LM10. ( G ) Comparative analysis of serum EVs isolated by the ultracentrifugation method from HCC patients (n = 15) and HVs (n = 15). *p < 0.05, **p < 0.01, ***p < 0.001 by Kruskal-Wallis test with Dunn’s multiple comparison test.

    Article Snippet: Serum MFG-E8 levels were measured using an ELISA kit (DFGE80; R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

    Techniques: Isolation, Expressing, Western Blot, Concentration Assay, Comparison